Molecularly targeted therapies for breast cancer - PubMed (original) (raw)

Review

Molecularly targeted therapies for breast cancer

Timothy J Hobday et al. Cancer Control. 2005 Apr.

Free article

Abstract

Background: The management of patients with localized and advanced breast cancer continues to evolve. Chemotherapy, endocrine therapy, and trastuzumab are effective therapies but leave considerable room for improvement. As the cellular aberrations inherent to cancer cells in general and breast cancer cells specifically are better understood, therapies to target specific cellular pathways continue to be developed with the goal of expanding available effective therapy through better patient selection.

Methods: We conducted a computerized search of the medical literature as well as a manual search of selected meeting abstracts.

Results: Several targeted therapies are in phase III clinical trials testing their promise in the treatment of breast cancer. Many other agents are completing phase I and II testing. An overview of the most promising agents in clinical development is discussed herein.

Conclusions: Targeted therapy for breast cancer is a reality at this time, and several new agents hold promise for expanding and refining the pool of patients likely to further benefit from this approach in the near future.

PubMed Disclaimer

Cited by

lncRNA Gene Signatures for Prediction of Breast Cancer Intrinsic Subtypes and Prognosis.
Zhang S, Wang J, Ghoshal T, Wilkins D, Mo YY, Chen Y, Zhou Y. Zhang S, et al. Genes (Basel). 2018 Jan 26;9(2):65. doi: 10.3390/genes9020065. Genes (Basel). 2018. PMID: 29373522 Free PMC article.
BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Bouchalova K, Svoboda M, Kharaishvili G, Vrbkova J, Bouchal J, Trojanec R, Koudelakova V, Radova L, Cwiertka K, Hajduch M, Kolar Z. Bouchalova K, et al. Tumour Biol. 2015 Jun;36(6):4243-52. doi: 10.1007/s13277-015-3061-7. Epub 2015 Jan 24. Tumour Biol. 2015. PMID: 25616695
Integrated analysis identifies interaction patterns between small molecules and pathways.
Li Y, Li W, Chen X, Jiang H, Sun J, Chen H, Lv S. Li Y, et al. Biomed Res Int. 2014;2014:931825. doi: 10.1155/2014/931825. Epub 2014 Jul 13. Biomed Res Int. 2014. PMID: 25114931 Free PMC article.
Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition.
Muthuswami M, Ramesh V, Banerjee S, Viveka Thangaraj S, Periasamy J, Bhaskar Rao D, Barnabas GD, Raghavan S, Ganesan K. Muthuswami M, et al. PLoS One. 2013 Oct 17;8(10):e77553. doi: 10.1371/journal.pone.0077553. eCollection 2013. PLoS One. 2013. PMID: 24147022 Free PMC article.
Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer.
Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe S. Liu X, et al. Mol Cancer Ther. 2012 Jul;11(7):1421-31. doi: 10.1158/1535-7163.MCT-12-0026. Epub 2012 May 2. Mol Cancer Ther. 2012. PMID: 22553354 Free PMC article.

Molecularly targeted therapies for breast cancer - PubMed (original) (raw)